Accordingly, overexpression of TAZ rendered lung cancer cells with EGFR (epidermal growth factor receptor) mutation resistant to gefitinib, indicating that combinational targeting on both EFGR and TAZ could enhance the efficacy of EGFR tyrosine kinase inhibitors to overcome the acquired resistance of NSCLC [38]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.